The promise of personalized medicine depends on discovering critical insights into tumor biology that can uncover new therapeutic targets and biomarker signatures that inform care. Structural variants (SVs) are a hallmark of cancer, yet current cytogenetic and molecular methods fail to detect all classes and sizes of SVs, missing a significant amount of information critical to understanding cancer biology.^1-16 Studies have shown that a significant portion of SVs detected by optical genome mapping (OGM) are being missed by traditional cytogenetic and next-generation sequencing (NGS) approaches.^2,16,17

Leverage OGM to maximize SV detection, so you can build comprehensive genomic profiles of hematological malignancies and solid tumors, deepening your understanding of cancer biology and unlocking new precision medicine possibilities.